FDA Warns Amazon, Walmart Over Unapproved Herpes Claims

FDA posted nine warning letters on 6 October 2026, all dated 1 October, over topical products marketed as treatments for genital herpes and genital warts — conditions no over-the-counter drug has ever been approved to treat, cure or prevent. Seven letters went to small manufacturers. Two went to Amazon and Walmart, not as marketplaces hosting someone else's listing, but as the companies whose own fulfillment networks moved the product to the buyer's door.

The underlying violation: no approved OTC drug treats an STI

FDA's position across all nine letters rests on a single, settled fact: there is no FDA-approved over-the-counter drug for treating, curing, mitigating or preventing genital herpes, genital warts, or any other sexually transmitted infection. A topical product marketed with claims to do any of those things is, by definition, an unapproved new drug under the Federal Food, Drug, and Cosmetic Act — whatever ingredients it contains or however it is labelled. Several of the cited products describe themselves as homeopathic or plant-based, framing that does not exempt a product from new-drug status once its marketing claims cross into treating a specific disease. FDA's stated concern extends beyond the false-claim itself: a consumer who believes a $20 cream is treating their herpes outbreak may delay or forgo the antiviral therapy and clinical follow-up that condition actually calls for, with downstream risk the agency's letters describe as including complications from untreated infection.

Why Amazon and Walmart, specifically

The letters to Amazon and Walmart are not simply holding the retailers responsible for a third-party seller's product listing. FDA's letters describe products purchased directly on amazon.com and walmart.com and shipped through each company's own logistics arm — Fulfillment by Amazon in Amazon's case, Walmart Fulfillment Services in Walmart's. That distinction is the letters' operative legal theory: a retailer that physically stores, packs and ships a product through its own fulfillment infrastructure has, in FDA's view, introduced or delivered that product into interstate commerce itself, a basis for liability independent of who manufactured the product or who listed it for sale on the platform. Neither retailer manufactures the cited products; RoyceDerm, Terramed, Aidance Scientific and the other named manufacturers do. The retailers are implicated because of how the product reached the buyer, not who made it.

Not FDA's first use of this theory

This is not a new enforcement posture for FDA, and Amazon in particular has seen it before: the agency sent Amazon a warning letter in June 2026 over phimosis and balanitis creams that moved through the same fulfillment network, and has applied comparable fulfillment-based reasoning against both Amazon and Walmart in earlier cases involving an unapproved joint supplement and a molluscum contagiosum treatment. What distinguishes the 1 October sweep is its scale: ten recipients, cutting across manufacturers and both major retailers simultaneously, for a single category of claim. For a retailer the size of Amazon or Walmart, that scale is the signal — it suggests FDA is treating fulfillment-network liability as a standing enforcement tool for OTC and homeopathic product claims generally, not a one-off response to a single complaint.

What this means for compliance teams

For any retailer operating its own fulfillment service, the operative lesson is that FDA does not treat warehousing and shipping as a neutral, liability-free role once a product's marketing claims cross into drug territory — quality and regulatory teams reviewing OTC, homeopathic, supplement and wellness products moving through owned fulfillment need to screen for disease-treatment claims before the product ships, not rely on third-party sellers' own listings to self-police. For manufacturers, the letters are a reminder that ‘homeopathic’ or ‘natural’ labelling does not change a product's regulatory status once its marketing makes a specific disease claim; FDA's enforcement interest tracks the claim, not the ingredient list.

Frequently asked questions

What did FDA cite Amazon and Walmart for?

Warning letters dated 1 October 2026 (MARCS-CMS 736006 for Amazon.com, Inc. and 736557 for Walmart, Inc.) cite both retailers for introducing unapproved new drugs into interstate commerce — topical products marketed with claims to treat genital herpes and, in some cases, genital warts, none of which FDA has approved for either indication.

Why are the retailers named, not just the manufacturers?

FDA's letters reach Amazon and Walmart because the cited products moved through each company's own fulfillment network — Fulfillment by Amazon and Walmart Fulfillment Services — rather than shipping directly from a third-party seller. FDA's theory treats that fulfillment role as introducing the product into interstate commerce in its own right, independent of who manufactured it or listed it for sale.

Which products are named?

Among the products cited across the nine letters: FemiClear, HerpCare Ointment, HerpCare Spray, Genital Herpes Intimate Wash, Herstat GST, RoyceDerm Herpes Relief Cream, Terragen HG Formula, HClear for Him, and HerpCare Genital Wart Remover Ointment, several marketed as homeopathic or plant-based.

Has FDA used this theory before?

Yes. FDA sent Amazon a warning letter in June 2026 over unapproved phimosis and balanitis creams moved through its fulfillment network, and used a similar theory against both Amazon and Walmart in earlier joint-supplement and molluscum-treatment cases. This sweep extends the same fulfillment-based liability theory to STI-claim topicals across ten recipients at once.